GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

VaxCell Biotherapeutics Co 323990.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

4,835

+29.97%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩7.06bn

FY2018FY2025

Net income

−₩13.34bn

FY2018FY2025

Free cash flow

−₩17.41bn

FY2018FY2025

Shareholders' equity

₩61.13bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue₩7.06bn₩1.90bn₩13.7m—————
Research and development₩5.64bn₩6.04bn₩4.92bn₩2.17bn₩1.76bn₩987.2m——
Operating income−₩15.49bn−₩15.05bn−₩11.51bn−₩8.22bn−₩5.90bn−₩4.25bn−₩4.01bn−₩2.42bn
Net income−₩13.34bn−₩10.62bn−₩10.27bn−₩6.83bn−₩4.76bn−₩3.98bn−₩1.25bn−₩6.45bn
Diluted earnings per share-575.65-463.71-446.83-448.34-235.74-264.79-72.58-909.41

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets₩66.90bn₩76.94bn₩84.98bn₩24.16bn₩31.28bn₩35.50bn₩10.04bn₩12.26bn
Cash and short-term investments———₩20.39bn₩27.31bn₩18.90bn₩8.07bn₩11.45bn
Total liabilities₩5.77bn₩4.95bn₩1.49bn₩835.8m₩1.20bn₩830.1m₩964.5m₩24.45bn
Debt—₩2.27bn₩361.2m₩105.2m₩220.4m₩339.1m₩463.6m₩12.28bn
Shareholders' equity₩61.13bn₩71.99bn₩83.49bn₩23.33bn₩30.08bn₩34.67bn₩9.07bn−₩12.20bn
Shares outstanding23m23m23m15m20m15m17m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−₩10.63bn−₩10.70bn−₩9.42bn−₩6.04bn−₩4.66bn−₩3.30bn−₩3.59bn−₩1.99bn
Capital spending−₩6.78bn−₩4.07bn−₩198.5m−₩290.2m−₩2.23bn−₩26.9m−₩902.7m−₩467.0m
Free cash flow−₩17.41bn−₩14.76bn−₩9.62bn−₩6.33bn−₩6.89bn−₩3.33bn−₩4.49bn−₩2.46bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩1.62bn₩1.54bn₩1.70bn₩1.65bn₩1.99bn₩1.72bn₩1.36bn₩482.9m
Operating income−₩5.01bn−₩4.62bn−₩3.65bn−₩3.44bn−₩4.19bn−₩4.29bn−₩4.37bn−₩3.53bn
Net income−₩4.05bn−₩3.97bn−₩4.22bn−₩2.68bn−₩3.82bn−₩2.62bn−₩3.32bn−₩2.41bn
Diluted earnings per share-174.61-171.27-182.07-115.78-164.93-112.87-144.88-104.89
Cash from operations−₩2.93bn−₩3.17bn−₩1.66bn−₩2.85bn−₩2.63bn−₩3.48bn−₩10.70bn−₩7.29bn
Capital spending−₩707.0m−₩906.0m−₩2.48bn−₩3.49bn−₩788.0m−₩19.0m−₩4.07bn−₩3.44bn
Free cash flow−₩3.64bn−₩4.07bn−₩4.15bn−₩6.34bn−₩3.41bn−₩3.50bn−₩14.76bn−₩10.73bn
Total assets₩58.68bn₩63.60bn₩66.90bn₩70.50bn₩72.81bn₩76.74bn₩76.94bn₩80.57bn
Cash and short-term investments—————₩33.13bn₩35.51bn₩40.50bn
Debt—————₩1.53bn₩1.40bn₩1.56bn
Shareholders' equity₩53.27bn₩57.22bn₩61.13bn₩65.22bn₩67.82bn₩71.57bn₩71.99bn₩75.05bn

Financial ratios

Data as of 4 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin-219.5%-792.8%-83848.0%—————
Net margin-189.1%-559.4%-74865.8%—————
Return on equity-21.8%-14.8%-12.3%-29.3%-15.8%-11.5%——
Return on assets-19.9%-13.8%-12.1%-28.2%-15.2%-11.2%——
Revenue growth271.6%13737.3%——————
Earnings growth25.6%3.4%50.5%43.3%19.5%217.8%——
Current ratio8.53x13.87x55.43x68.06x71.88x32.29x——
Debt to equity———0.00x0.00x0.00x0.00x-1.01x
Equity ratio91.4%93.6%98.3%96.5%96.2%97.7%——
Interest coverage-68.96x-66.87x-263.52x-453.36x-204.16x-112.38x——
R&D as a share of sales79.9%318.1%35844.5%—————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income23.5%29.5%—
Net income25.0%27.3%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-341.1%———
Net margin-267.6%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-17.4-22.5-50.2-59.5-143.9-493.9
Price to sales32.8125.8————

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 6-for-5 split · 10 Nov 2023
  • 855-for-802 split · 20 Sept 2023
  • 2-for-1 split · 30 Dec 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.